A method of enhancing absorption of a therapeutic agent sublingually in a person configured to treat chronic graft-versus-host disease (cGVHD) or aphthous stomatitis. The method includes administering a therapeutically effective amount of the therapeutic agent sublingually in a person and then inserting for a predetermined treatment period a device in an oral cavity of the person, wherein the device comprising an oral retention portion that is configured to be retained in the oral cavity from the predetermined treatment period and further configured to enhance absorption of the therapeutic agent sublingually.

The invention relates to a mouthpiece for a product dispensing device including a product dispensing duct defining a longitudinal axis and including a connection opening designed to be connected to a dispensing member of the product dispensing device, and a dispensing opening designed to open freely into the mouth of a user, and a lingual cavity designed to receive at least one end of the tongue of the user, including a lingual opening allowing the tongue to be inserted into the lingual cavity and a contact surface designed to form a target for one end of the tongue of the user.

The invention also relates to a product dispensing device and to a method for dispensing a product.

An electrically-powered inhalation device for delivery of an aerosol to the oropharynx of a user comprises respective proximal and distal portions, the proximal portion including an inlet for a liquid, the distal portion including an aerosol outlet defining a mist-exiting location and a piezo assembly including an ultrasonically vibrable mesh membrane, for producing, upon electrical activation, a mist comprising droplets of the liquid, the mesh membrane defining a mist-generating location; and an intermediate portion disposed distally from the proximal portion and proximally from the distal portion, wherein the distal portion is dimensioned to vertically span the user's oral cavity from tongue to hard-palate when the user's lips and/or teeth are transversely engaged with the intermediate portion, so as to place the mist-exiting location in fluid communication with the user's oropharynx.

Surface debriding systems and instruments are provided that efficiently and effectively dislodge and remove debris, coatings, microorganisms and fluids from the dorsum of the tongue or other surfaces. The instrument has a debriding surface with cleaning elements and a number of spaced apart openings to a hollow interior that is configured to couple with a vacuum source. The shape of the openings may be configured to amplify suction force from the vacuum source. The system also has a vacuum source and a collecting vessel with backflow valves to store removed material and to stop movement of material into the vacuum source or back out to the instrument. The system can be self-contained or the instrument may be coupled to a dental high-volume evacuator (HVE) vacuum source.

Example devices and methods of tongue stimulation for communication of information to a user are disclosed herein. In an example, a tongue stimulation device may include a body configured to be placed entirely within a mouth of the user and atop the tongue of the user. An array of electro-tactile elements may be distributed on the body, wherein each of the electro-tactile elements is configured to stimulate an area of the tongue adjacent the electro-tactile element. A wireless receiver coupled to the body may be configured to receive stimulation information wirelessly from outside the mouth of the user. At least one processing unit coupled to the body may be configured to transform the received stimulation information into a stimulation signal for each of the electro-tactile elements, and to provide the stimulation signals to the electro-tactile elements.

A sleep apnea syndrome symptom improvement aid 1 includes a sandwiching target 10 sandwiched by front teeth of a patient, a tongue presser 20 extending from the sandwiching target 10 to the vicinity of the soft palate of the patient and including an elastic body configured to press the tongue, and a detector 30 configured to detect at least one of a vital sign or a salivary component of the patient.

A method of enhancing absorption of a therapeutic agent sublingually in a person. The method includes administering a therapeutically effective amount of the therapeutic agent sublingually in a person and then inserting for a predetermined treatment period a device in an oral cavity of the person, wherein the device comprising an oral retention portion that is configured to be retained in the oral cavity from the predetermined treatment period and further configured to enhance absorption of the therapeutic agent sublingually.

A device for alleviating obstructive sleep apnea, comprising: a base fitted and fixed to an user's head and having a passage portion; an adjustment element extending into the passage portion and undergoing relative displacement therein; a locking element disposed at the passage portion, wherein an user uses the locking element to fix the adjustment element in place to limit the relative displacement of the adjustment element; a suction member undergoing relative displacement relative to the passage portion together with the adjustment element and having a channel, wherein the channel extends into the adjustment element, undergoes relative displacement in the adjustment element, and connects to a tongue fixing portion disposed at the front end of the user's tongue; and a negative pressure source being mounted on the base and in communication with the channel, providing a negative pressure to the user's tongue in contact with the tongue fixing portion.

The present disclosure relates to an encapsulated, pressurized, sublingual nano mist vapor delivery device, which may deliver a formula, including a micellized liquid nicotine formula. The device comprises a protective receptacle or housing, which preferably houses at least one canister, and a receptacle cap. The device may also comprise a custom actuator in communication with a metered valve for delivering a precise, known volume of at least one micellized liquid nicotine formula. Methods of manufacture and use are also disclosed herein.

A system (SYS) and related method for imaging support. The system (SYS) comprises a stimulus delivery component (SDC) configured to cause a chemoreceptor stimulus in a patient residing in or at an imaging apparatus (IA). A response measuring component (RMC) measure a response of the patient to the stimulus, and a decision logic (DL) establishes, based on the measured response, a sedation status of the patient for the purpose of imaging the patient. An imaging operation can be modified, for instance, halted if the patient is no longer sufficiently sedated.